Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
PUMA BIOTECHNOLOGY, INC. : PBYI Stock Price | US74587V1070 | MarketScreener
Puma Biotechnology Stock News (PBYI) - Page 5 - Public.com
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology, Inc. - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS
Articles with Puma Biotechnology
Puma Biotechnology
News Release
Puma Biotechnology, Inc. - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
News Release
Puma Biotechnology
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI | Business Wire
Puma Biotechnology
Puma Biotechnology, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Puma Biotechnology: Increasing Our Exposure (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
